Troriluzole in Adult Subjects With Spinocerebellar Ataxia
The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
- Drug: Troriluzole
- OR placebo
For study details, including how the study is designed, please contact Stephen Gullet:
- 18 - 75 years old
- Subjects with a known or suspected diagnosis of the following specific hereditary ataxias: SCA1, SCA2, SCA3, SCA6, SCA7, SCA8 and SCA10;
- Ability to ambulate 8 meters without human assistance (canes and other devices allowed)
- Screening f-SARA total score ≥3;
- Score of ≥1 on gait subsection of the f-SARA
Additional criteria apply, please contact Stephen Gullet for more information:
Can be done from home
KeywordsSpinocerebellar Ataxia, Neurology, Ataxia
Principal InvestigatorS.H. Subramony, MD
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.